Catheter News and Research

RSS

In medicine, a catheter is a tube that can be inserted into a body cavity, duct, or vessel. Catheters . In most uses, a catheter is a thin, flexible tube ("soft" catheter), though in some uses, it is a larger, solid ("hard") catheter. A catheter left inside the body, either temporarily or permanently, may be referred to as an indwelling catheter. A permanently inserted catheter may be referred to as a permcath.

Stereotaxis to be featured prominently in 31st HRS

Stereotaxis' safety and efficacy in the treatment of patients with complex arrhythmias such as atrial fibrillation, ventricular tachycardia, and congenital heart defects will be featured prominently in the scientific program of the 31st Annual Heart Rhythm Scientific Sessions in Denver, Colorado. Eight podium presentations and eight posters will underscore the broad clinical leadership that Stereotaxis has achieved in the treatment of patients with complex cardiac arrhythmias.

13 May 2010

New Melody Transcatheter Pulmonary valve helps congenital heart defect patients avoid multiple surgeries

Congenital heart defects are the most common type of major birth defect in the U.S., affecting about 25,000 babies each year. Now, a new valve being used at the University of Michigan's C.S. Mott Children's Hospital Congenital Heart Center can help patients delay or avoid multiple surgeries.

13 May 2010

St. Jude Medical to display new products, clinical solutions at Heart Rhythm 2010

St. Jude Medical, Inc., a global medical device company, today announced it will display a number of new products and clinical solutions from the company's Cardiac Rhythm Management and Atrial Fibrillation Divisions at Heart Rhythm 2010, the Heart Rhythm Society's 31st Annual Scientific Sessions.

13 May 2010

Resverlogix' Phase 2 ASSERT trial dosing complete ahead of schedule

Resverlogix is pleased to announce that the Phase 2 ASSERT clinical trial for its lead drug, RVX-208, a small molecule therapy for the treatment of atherosclerosis has now completed dosing. "The completion of dosing for our Phase 2 ASSERT trial, five months ahead of schedule and without any alterations to the dose levels of the three drug receiving cohorts, is another major step forward in the development of this important cardiovascular drug.

13 May 2010

BSX receives CE Mark approval for TAXUS Element Paclitaxel-Eluting Coronary Stent System

Boston Scientific Corporation today announced it has received CE Mark approval for its TAXUS Element Paclitaxel-Eluting Coronary Stent System, the Company's third-generation drug-eluting stent technology. This approval includes a specific indication for the treatment of diabetic patients.

13 May 2010

Boston Scientific receives CE Mark approval for TAXUS Element Paclitaxel-Eluting Coronary Stent System

Angiotech Pharmaceuticals, Inc. today announced that its corporate partner, Boston Scientific Corporation, has received CE Mark approval for its TAXUS(R) Element(TM) Paclitaxel-Eluting Coronary Stent System, Boston Scientific's third-generation drug-eluting stent (DES) technology.

13 May 2010

NovaBay first-quarter net loss increases to $1.6 million

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today reported financial results for the first quarter of 2010.

12 May 2010

RevMed partners with Santa Monica to set up safety syringe manufacturing facility in Brazil

Revolutions Medical Corporation, has signed an agreement of understanding for the setting up of a manufacturing facility in Brazil to produce the RevVac safety syringe for domestic and global markets and to facilitate distribution throughout South America.

12 May 2010

Stereotaxis launches Vdrive module for remote manipulation of diagnostic devices during EP procedures

Stereotaxis, Inc. today announces the introduction of its new Vdrive™, an expansion of its Magnetic Navigation platform that facilitates remote manipulation of diagnostic devices used during electrophysiology (EP) procedures. The company is planning to preview the Vdrive at the HRS meeting this week, and will be commercially available when regulatory processes are complete.

12 May 2010

Update on Nymox Pharmaceutical's Phase 3 program for NX-1207

Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia. The most recent Safety Monitoring Committee meeting of April 30, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 indicated no significant safety concerns for the trials to date.

12 May 2010

IMBio receives regulatory concurrence from FDA to market OCL 500 microspheres in the U.S.

IMBiotechnologies Ltd., a privately held biotechnology company focused on developing medical device products for use in the area of embolotherapy, today announced that it has received regulatory concurrence from the United States Food and Drug Administration to market its lead product, Occlusin 500 Artificial Embolization Device in the U.S. for the treatment of unresectable/inoperable hypervascularized tumours.

12 May 2010

Cardima implements reverse stock split

Cardima, Inc., a medical device company focused on the treatment of atrial fibrillation and manufacturer of the Cardima Surgical Ablation System, announced today that its common stock will commence trading under the new ticker symbol, "CADMD" following the implementation of a reverse stock split in a 1-for-10 ratio.

11 May 2010

BIOTRONIK launches TactiCath irrigated RF contact force ablation catheter for treating AF

BIOTRONIK SE & Co. KG, a leading manufacturer of implantable cardiac devices and pioneer of remote monitoring technologies today announced the market release of the TactiCath catheter. The TactiCath catheter, an Endosense company product, is an irrigated RF contact force ablation catheter with features that offer a major advance in ablation therapy for patients with cardiac arrhythmias and particularly Atrial Fibrillation (AF).

11 May 2010

Aastrom Biosciences reports third quarter 2010 FY results

Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported financial results for its third fiscal quarter ended March 31, 2010, and also announced progress in its late-stage clinical development programs and corporate operations.

11 May 2010

Endosense commences enrollment in EFFICAS I study with TactiCath force-sensing catheter

Endosense, a Swiss medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced it has enrolled the first patients in EFFICAS I, the first study of the EFFICAS series. These patients were enrolled in Na Homolce Hospital, Prague, Czech Republic and treated by Petr Neuzil, M.D. and Vivek Reddy, M.D.

10 May 2010

Asthmatx announces first U.S. patient treated with BT delivered by Alair System

Asthmatx, Inc. reported today that doctors at Virginia Hospital Center in Arlington, Va., recently treated the first U.S. patient with bronchial thermoplasty (BT) delivered by the Alair® System, the first device-based asthma treatment approved by the U.S. Food and Drug Administration (FDA).

10 May 2010

AngioDynamics introduces redesigned Centros self-centering chronic hemodialysis access catheter

AngioDynamics announced today it has achieved the national launch of the newly redesigned Centros self-centering, chronic hemodialysis access catheter.

10 May 2010

CardioMEMS completes $37.9M financing

CardioMEMS, Inc., a medical technology company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body, today announced the completion of a $37.9M financing. The financing provides the company with capital to complete the company's CHAMPION clinical trial.

7 May 2010

Cytori Therapeutics to initiate European medical device approval study for Celution System

The first clinical trial of adipose (fat) tissue-derived stem and regenerative cells for the treatment of heart attacks showed a substantial reduction in the size of injury to the heart, an improvement in the amount of blood supply to the heart muscle, and a corresponding functional improvement in the amount of blood the heart can pump.

7 May 2010

Stereotaxis reports $10.6 million revenue for first-quarter 2010

Stereotaxis, Inc. today reported financial results for the first quarter ended March 31, 2010 highlighted by recurring revenue and gross margin achieving record levels while operating losses continued to decline. In addition, the Company reported that its efforts to drive clinical adoption within the U.S. market are favorably impacting utilization rates.

6 May 2010

Catheter News and Research

Further Reading

Stereotaxis to be featured prominently in 31st HRS

New Melody Transcatheter Pulmonary valve helps congenital heart defect patients avoid multiple surgeries

St. Jude Medical to display new products, clinical solutions at Heart Rhythm 2010

Resverlogix' Phase 2 ASSERT trial dosing complete ahead of schedule

BSX receives CE Mark approval for TAXUS Element Paclitaxel-Eluting Coronary Stent System

Boston Scientific receives CE Mark approval for TAXUS Element Paclitaxel-Eluting Coronary Stent System

NovaBay first-quarter net loss increases to $1.6 million

RevMed partners with Santa Monica to set up safety syringe manufacturing facility in Brazil

Stereotaxis launches Vdrive module for remote manipulation of diagnostic devices during EP procedures

Update on Nymox Pharmaceutical's Phase 3 program for NX-1207

IMBio receives regulatory concurrence from FDA to market OCL 500 microspheres in the U.S.

Cardima implements reverse stock split

BIOTRONIK launches TactiCath irrigated RF contact force ablation catheter for treating AF

Aastrom Biosciences reports third quarter 2010 FY results

Endosense commences enrollment in EFFICAS I study with TactiCath force-sensing catheter

Asthmatx announces first U.S. patient treated with BT delivered by Alair System

AngioDynamics introduces redesigned Centros self-centering chronic hemodialysis access catheter

CardioMEMS completes $37.9M financing

Cytori Therapeutics to initiate European medical device approval study for Celution System

Stereotaxis reports $10.6 million revenue for first-quarter 2010

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News